Bulk Pharmaceutical API Sources for PAZOPANIB HYDROCHLORIDE

Bulk Pharmaceutical API Sources for PAZOPANIB HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		11525740
Exclusive Chemistry Ltd		EC-000.2347
ChemMol		49410323

Bulk Active Pharmaceutical Ingredient (API) Sources for Pazopanib Hydrochloride: An Industry Overview

Last updated: July 27, 2025

Introduction

Pazopanib hydrochloride, a potent tyrosine kinase inhibitor primarily used in cancer therapy, specifically for renal cell carcinoma and soft tissue sarcoma, demands high purity and stringent quality standards for its active pharmaceutical ingredient (API). As the oncology market continues to expand, the sourcing strategies for bulk APIs like pazopanib hydrochloride have become a critical component of pharmaceutical supply chain management. This article explores the leading API manufacturers, the landscape of sourcing options, and strategic considerations relevant for stakeholders in the pharmaceutical and biotech industries.

---

Global API Manufacturing Landscape for Pazopanib Hydrochloride

The API manufacturing sector is characterized by a complex network of global suppliers, governed by regulatory standards like the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and the International Council for Harmonisation (ICH). For pazopanib hydrochloride, manufacturing is concentrated among a few key players with capabilities for complex synthesis, high-purity production, and compliance with Good Manufacturing Practices (GMP).

Leading API Manufacturers

1. Miyoshi Pharmaceutical Co., Ltd.
   Miyoshi has established itself as a pioneer in the synthesis of kinase inhibitors, including pazopanib hydrochloride. The company's extensive process development capabilities enable high-quality API production, compliant with global standards. Miyoshi supplies APIs primarily to North America and Europe, leveraging its GMP-certified facilities.

2. Hengyi Pharmaceutical Co., Ltd.
   Based in China, Hengyi is an emerging player with aggressive investments in API manufacturing infrastructure for oncology therapeutics. The company has obtained regulatory approvals for several APIs, including pazopanib hydrochloride, and offers competitive pricing due to its manufacturing scale.

3. Suwko Pharmaceutical Co., Ltd.
   Focused on the Asian market, Suwko has developed a robust synthesis route for pazopanib hydrochloride, adhering to international cGMP standards. The firm emphasizes stringent quality control and has partnered with global distributors.

4. North American and European Contract Manufacturing Organizations (CMOs)
   Notable CMOs like Lonza, WuXi AppTec, and Ricerca Biosciences possess the capacity to produce pazopanib hydrochloride under strict GMP conditions. These providers often supply customized formulations and can scale production volumes efficiently.

5. Generic API Producers
   Companies such as Dr. Reddy's Laboratories and NATCO Pharma have entered the pazopanib market offering high-quality, cost-effective APIs suited for generic formulations. Such manufacturers typically leverage existing synthesis pathways with innovations to optimize cost and yield.

---

Sourcing Strategies and Considerations

1. Quality and Regulatory Compliance
Ensuring API purity, bioavailability, and batch-to-batch consistency is paramount. Suppliers must demonstrate compliance with ICH Q7 guidelines and possess comprehensive documentation, including Certificates of Analysis (CoA), stability data, and site inspection audits.

2. Cost and Supply Security
Price competitiveness remains a vital factor, especially as patent exclusivity expires. However, long-term supply security often favors established relationships with GMP-certified manufacturers with proven manufacturing records. Dual sourcing strategies, involving multiple suppliers across regions, mitigate risks related to geopolitical issues, regulatory delays, and supply chain disruptions.

3. Intellectual Property and Patent Considerations
Although pazopanib was originally developed by GlaxoSmithKline, subsequent patent expiries and patent challenges in various jurisdictions have increased access to APIs from multiple suppliers. Proper legal review ensures sourcing practices remain compliant with applicable intellectual property laws.

4. Scalability and Lead Times
Manufacturers capable of producing large batch sizes with short lead times support dynamic clinical development and commercial manufacturing. Early engagement with suppliers helps establish reliable timelines and volume commitments.

---

Emerging Trends Impacting API Sourcing for Pazopanib Hydrochloride

• Regional Diversification: Increasing adoption of regional manufacturing hubs in Asia and Eastern Europe to reduce lead times and logistical complexity.
• Manufacturing Innovations: Advances in green chemistry and process intensification to improve yield, reduce waste, and enhance sustainability.
• Quality Benchmarking: Growing importance of analytical techniques such as HPLC, NMR, and mass spectrometry to validate API integrity.
• Regulatory Harmonization: Increased cross-border recognition of GMP certifications streamlining supplier qualification processes.

---

Challenges in API Sourcing

Despite the expanding supplier pool, challenges persist:

• Regulatory Hurdles: Variations in regional standards require meticulous documentation and testing.
• Market Fluctuations: Demand fluctuation influences pricing and supply stability.
• IP and Patent Barriers: Patent litigation or litigation threats may restrict or complicate sourcing options.
• Supply Chain Disruptions: Global disruptions, such as those caused by geopolitical tensions or pandemics, impede consistent API flow.

---

Conclusion

The sourcing landscape for pazopanib hydrochloride API is characterized by a mixture of established manufacturers, emerging suppliers, and contract manufacturing organizations capable of delivering high-quality products at competitive prices. Strategic sourcing involves balancing quality, cost, supply security, and regulatory compliance to ensure uninterrupted clinical and commercial manufacturing.

Pharmaceutical companies considering pazopanib hydrochloride sourcing should prioritize validated suppliers with proven regulatory track records, diversify their supplier base to avoid bottlenecks, and stay abreast of technological innovations that refine API production. As the oncology pipeline evolves, so too will the dynamics of API sourcing, underscoring the need for agility and strategic foresight.

---

Key Takeaways

• The primary API manufacturers for pazopanib hydrochloride include Miyoshi, Hengyi, Suwko, and major CMOs like WuXi AppTec and Lonza.
• Ensuring GMP compliance, quality, and supply security is paramount when selecting API sources.
• Diversification of suppliers mitigates risks associated with regional, geopolitical, and logistical disruptions.
• Technological and regulatory trends favor regional manufacturing hubs, supporting faster and more reliable API supply chains.
• Continuous monitoring of intellectual property rights and patent landscapes remains essential in API procurement strategies.

---

FAQs

1. What are the critical quality attributes for sourcing pazopanib hydrochloride APIs?
Critical quality attributes include high purity (typically >99%), chemical stability, consistent potency, absence of residual solvents and contaminants, and compliance with pharmacopeial standards such as USP or EP.

2. How do regulatory standards influence API sourcing decisions?
Manufacturers must have GMP certification and robust quality management systems. Regulatory agencies perform site audits and review documentation, so suppliers with established global approvals facilitate smoother registration and market access.

3. Are there regional differences in API manufacturing quality?
While some regions have historically faced quality perception challenges, many Asian and Eastern European manufacturers now achieve international GMP certification, aligning their quality standards with Western regulatory expectations.

4. How does patent expiration impact API sourcing for pazopanib hydrochloride?
Patent expiry typically opens the market for generic API manufacturing, increasing the supplier pool and competitive pricing, but legal diligence is necessary to avoid infringing remaining patents or exclusivities.

5. What future trends could influence pazopanib hydrochloride API sourcing?
Emerging trends include process innovation for greener synthesis, regional manufacturing decentralization, and increasing use of digitalization for supplier qualification and quality monitoring.

---

References

1. U.S. Pharmacopeia. (2022). USP Monographs for Oncology APIs.
2. European Directorate for the Quality of Medicines & HealthCare. (2022). European Pharmacopoeia standards for anticancer APIs.
3. International Council for Harmonisation. (2022). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
4. Industry reports on oncology API manufacturing, IQVIA, 2022.
5. Company disclosures and annual reports of Miyoshi Pharmaceutical, Hengyi Pharmaceutical, and major CMOs.